Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor

Orlistat, an antiobesity drug, is cytostatic and cytotoxic to tumor cells (1). The antitumor activity of orlistat can be attributed to its ability to inhibit the thioesterase domain of fatty acid synthase (FAS). The objective of the present study was to test the effect of orlistat on endothelial cell proliferation and angiogenesis. Orlistat inhibits endothelial cell FAS, blocks the synthesis of fatty acids, and prevents endothelial cell proliferation. More significantly, orlistat inhibits human neovascularization in an ex vivo assay, which suggests that it may be useful as an antiangiogenic drug. The mechanism of these effects can be traced to the fact that orlistat prevents the display of the vascular endothelial growth factor (VEGF) receptor (VEGFR2/ KDR/Flk1) on the endothelial cell surface. Thus, orlistat is an antiangiogenic agent with a novel mechanism of action.—Browne, C. D., Hindmarsh, E. J., and Smith, J. W. Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J. 20, 2027–2035 (2006)

[1]  Ying Wang,et al.  FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis , 2005, Oncogene.

[2]  R. Motzer,et al.  Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) , 2005 .

[3]  G. Demetri,et al.  Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST , 2005 .

[4]  S. Ropero,et al.  Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[6]  Jeffrey W. Smith,et al.  Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity , 2004, Cancer Research.

[7]  P. Febbo,et al.  Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. , 2003, Molecular cancer research : MCR.

[8]  D. Mukhopadhyay,et al.  Heterotrimeric Gαq/Gα11 Proteins Function Upstream of Vascular Endothelial Growth Factor (VEGF) Receptor-2 (KDR) Phosphorylation in Vascular Permeability Factor/VEGF Signaling* , 2003, Journal of Biological Chemistry.

[9]  K. David,et al.  Key role of mitochondria in cerulenin-mediated apoptosis , 2002, Cell Death and Differentiation.

[10]  T. Roskams,et al.  Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer , 2002, International journal of cancer.

[11]  J. Burbaum,et al.  Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site‐directed probes , 2001, Proteomics.

[12]  A. Joshi,et al.  Mapping the functional topology of the animal fatty acid synthase by mutant complementation in vitro. , 2001, Biochemistry.

[13]  D. Chan,et al.  Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. , 2001, Cancer letters.

[14]  Ziwei Gu,et al.  Human fatty acid synthase: Role of interdomain in the formation of catalytically active synthase dimer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Gorospe,et al.  Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. , 2001, Cancer research.

[16]  B. Cravatt,et al.  Activity-based protein profiling: the serine hydrolases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Takenoshita,et al.  Fatty acid synthase expression in Japanese breast carcinoma patients. , 1999, International journal of molecular medicine.

[18]  Joseph A. DiGiuseppe,et al.  Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. , 1998, Cancer research.

[19]  D. Hicklin,et al.  Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy , 1998, Cancer and Metastasis Reviews.

[20]  Y. Furuya,et al.  Apoptosis of androgen-independent prostate cell line induced by inhibition of fatty acid synthesis. , 1997, Anticancer research.

[21]  W. Bornmann,et al.  The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Gansler,et al.  Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. , 1997, Human Pathology.

[23]  A. Witkowski,et al.  Mapping of functional interactions between domains of the animal fatty acid synthase by mutant complementation in vitro. , 1997, Biochemistry.

[24]  D. Maguire,et al.  A novel in vitro assay for human angiogenesis. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[25]  C. Jackisch,et al.  Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. , 1996, Cancer research.

[26]  G. Pasternack,et al.  Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. , 1996, Cancer research.

[27]  P. Visca,et al.  Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients , 1996, Cancer.

[28]  J. Martial,et al.  Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Jacobs,et al.  Fatty acid synthesis: a potential selective target for antineoplastic therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Wakil,et al.  The architecture of the animal fatty acid synthetase complex. IV. Mapping of active centers and model for the mechanism of action. , 1983, The Journal of biological chemistry.

[31]  S. Wakil,et al.  The architecture of the animal fatty acid synthetase. II. Separation of the core and thioesterase functions and determination of the N-C orientation of the subunit. , 1983, The Journal of biological chemistry.

[32]  J. Menéndez,et al.  Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. , 2005, Medical hypotheses.

[33]  D. Mukhopadhyay,et al.  Heterotrimeric G alpha q/G alpha 11 proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling. , 2003, The Journal of biological chemistry.

[34]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  C. Townsend,et al.  Synthesis and antitumor activity of an inhibitor of fatty acid synthase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Winer,et al.  The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. , 1992, Growth factors.